But if that 20% is not the bottleneck then at most your market is replacing the labor required to get that 20% to the next phase, plus you will probably not be able to capture full value here because of lab/model competition.
It’s only a benefit if it doesn’t bog the next stage down in noise. At that point it could be detrimental.
We already see that with software. It will be exactly the same with drug design.
My daughter is a leading biochem at one of the big pharma companies and that’s their principal worry about this. It’s really easy to create a lot of information these days which compromises the entire process.
It's also not the magical thing that will solve all diseases like some people who are starting to think we're going to enter the singularity soon seem to think.
But if that 20% is not the bottleneck then at most your market is replacing the labor required to get that 20% to the next phase, plus you will probably not be able to capture full value here because of lab/model competition.
It’s only a benefit if it doesn’t bog the next stage down in noise. At that point it could be detrimental.
We already see that with software. It will be exactly the same with drug design.
My daughter is a leading biochem at one of the big pharma companies and that’s their principal worry about this. It’s really easy to create a lot of information these days which compromises the entire process.
It's also not the magical thing that will solve all diseases like some people who are starting to think we're going to enter the singularity soon seem to think.